In addition to sponsoring its own research and collaborations, Lilly has programs for considering external requests for Lilly provision of study drug and/or financial support for external studies that are initiated, designed and sponsored by external researchers.
Lilly's Competitive Clinical Research Grant consist of publicly posted Request for Proposal (RFP) which includes details of specific areas of interest and timelines for review and approval. Researchers are encouraged to review the RFP, download the proposal form, and submit the completed proposal by the date specified in each RFP. Approved research proposals will be the responsibility of the grantee for the design, conduct the regulatory sponsorship. Initial reviews of the proposals are carried out by global committees comprised of Lilly medical and scientific staff members from relevant therapeutic areas. An external committee may be utilized to review and select the final proposals for approval.
Grant Opportunities
When you complete the proposal form, please email it to the designated email address in “Submit a Proposal”.
| Title | Application Due Date | Country | Focus Area | RFP Issue Date | Actions |
| Speed of improvement of moderate-to-severe Atopic Dermatitis (AD) in patients taking Lebrikizumab View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Dermatology | 2024-07-01T00:00:00.000Z | |
| Efficacy of Lebrikizumab in patients with different clinical phenotypes in the Atopic Dermatitis (AD) spectrum, including, but not limited to low body surface area involvement and high burden. View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Dermatology | 2024-07-01T00:00:00.000Z | |
| Lebrikizumab effect in adolescents with Atopic Dermatitis (AD) and involvement of visible/functional areas View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Dermatology | 2024-07-01T00:00:00.000Z | |
| The efficacy of Mirikizumab treatment in the over 60 population with moderate to severe Crohn’s disease and/or moderate to severe ulcerative colitis View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Gastroenterology | 2024-09-15T00:00:00.000Z | |
| The efficacy of Mirikizumab treatment in patients with perianal Crohn’s disease View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Gastroenterology | 2024-09-15T00:00:00.000Z | |
| Transmural healing with Mirikizumab treatment in patients with moderate to severe ulcerative colitis and/or moderate to severe Crohn’s disease View RFP (PDF) | 2024-11-15T00:00:00.000Z | United States | Gastroenterology | 2024-09-15T00:00:00.000Z |